daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.
Company profile
Ticker
DARE
Exchange
Website
CEO
Sabrina Martucci Johnson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cerulean Pharma Inc., Tempo Pharmaceuticals Inc
SEC CIK
Corporate docs
Subsidiaries
Daré Bioscience Operations, Inc. • Daré Bioscience Australia Pty Ltd • Pear Tree Pharmaceuticals, Inc. • Daré MBI Inc. ...
DARE stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
S-3
Shelf registration
29 Mar 24
S-3
Shelf registration
29 Mar 24
424B5
Prospectus supplement for primary offering
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
28 Mar 24
8-K
Daré Bioscience Announces Executive Team and Board of Directors Changes
26 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
D
$4.16 mm in options / securities to be acquired, sold $1.73 mm, 1 investor
26 Dec 23
Transcripts
DARE
Earnings call transcript
2023 Q3
9 Nov 23
DARE
Earnings call transcript
2023 Q2
10 Aug 23
DARE
Earnings call transcript
2023 Q1
11 May 23
DARE
Earnings call transcript
2022 Q4
30 Mar 23
DARE
Earnings call transcript
2022 Q3
11 Nov 22
DARE
Earnings call transcript
2022 Q2
10 Aug 22
DARE
Earnings call transcript
2022 Q1
13 May 22
DARE
Earnings call transcript
2021 Q4
1 Apr 22
DARE
Earnings call transcript
2021 Q3
11 Nov 21
DARE
Earnings call transcript
2021 Q2
13 Aug 21
Latest ownership filings
4
John A Fair
14 Mar 24
4
SABRINA MARTUCCI JOHNSON
14 Mar 24
4
MarDee Haring-Layton
14 Mar 24
3
MarDee Haring-Layton
29 Jan 24
4
Cheryl R Blanchard
21 Jun 23
4
Jessica D. Grossman
21 Jun 23
4
Robin Joan Steele
21 Jun 23
4
Sophia Nnenna Ononye-Onyia
21 Jun 23
4
Susan L. Kelley
21 Jun 23
4
WILLIAM H RASTETTER
21 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.23 mm | 14.23 mm | 14.23 mm | 14.23 mm | 14.23 mm | 14.23 mm |
Cash burn (monthly) | (no burn) | 2.18 mm | 2.80 mm | 3.50 mm | 2.66 mm | 3.05 mm |
Cash used (since last report) | n/a | 14.60 mm | 18.74 mm | 23.44 mm | 17.80 mm | 20.41 mm |
Cash remaining | n/a | -370.56 k | -4.51 mm | -9.21 mm | -3.57 mm | -6.18 mm |
Runway (months of cash) | n/a | -0.2 | -1.6 | -2.6 | -1.3 | -2.0 |
Institutional ownership, Q2 2023
9.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 3 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 5.11 bn |
Total shares | 9.24 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 3.44 mm | $3.13 bn |
Polaris Venture Partners Iii | 1.19 mm | $1.59 mm |
Hawley Roger | 944.96 k | $869.00 k |
Geode Capital Management | 817.34 k | $743.86 mm |
Renaissance Technologies | 718.82 k | $654.00 k |
CVI Investments | 599.90 k | $426.00 k |
BLK Blackrock | 416.06 k | $378.66 mm |
STT State Street | 247.71 k | $225.44 mm |
Susquehanna International | 164.02 k | $149.28 mm |
NTRS Northern Trust | 161.32 k | $146.81 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | John A Fair | Employee Stock Option Common stock | Grant | Acquire A | No | No | 0.46 | 290,000 | 133.40 k | 290,000 |
12 Mar 24 | Johnson Sabrina Martucci | Employee Stock Option Common stock | Grant | Acquire A | No | No | 0.46 | 750,000 | 345.00 k | 750,000 |
12 Mar 24 | MarDee Haring-Layton | Employee Stock Option Common stock | Grant | Acquire A | No | No | 0.46 | 290,000 | 133.40 k | 290,000 |
21 Jun 23 | Matz Gregory W | Stock Option Common stock | Grant | Acquire A | No | No | 0.96 | 40,000 | 38.40 k | 40,000 |
News
Brookline Capital Downgrades Dare Bioscience to Hold
17 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Apr 24
Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive
11 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
28 Mar 24
Dare Bioscience Q4 EPS $(0.06) Beats $(0.10) Estimate, Sales $1.81M Beat $1.79M Estimate
28 Mar 24